TY - JOUR
T1 - Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe
AU - AUTHOR GROUP
AU - Nakagawa, Fumiyo
AU - Lodwick, Rebecca
AU - Costagliola, Dominique
AU - van Sighem, Ard
AU - Torti, Carlo
AU - Podzamczer, Daniel
AU - Mocroft, Amanda
AU - Ledergerber, Bruno
AU - Dorrucci, Maria
AU - Cozzi-Lepri, Alessandro
AU - Jansen, Klaus
AU - Masquelier, Bernard
AU - García, Federico
AU - de Wit, Stephane
AU - Stephan, Christoph
AU - Obel, Niels
AU - Fätkenheuer, Gerd
AU - Castagna, Antonella
AU - Sambatakou, Helen
AU - Mussini, Cristina
AU - Ghosn, Jade
AU - Zangerle, Robert
AU - Duval, Xavier
AU - Meyer, Laurence
AU - Perez-Hoyos, Santiago
AU - Colin, Céline Fabre
AU - Kjaer, Jesper
AU - Chene, Genevieve
AU - Grarup, Jesper
AU - Phillips, Andrew
AU - de Luca, Andrea
AU - de Wolf, Frank
AU - Günthard, Huldrych
AU - Jørgensen, Louise
AU - Judd, Ali
AU - Lo Caputo, Sergio
AU - Noguera-Julian, Antoni
AU - Paraskevis, Dimitrios
AU - Paredes, Roger
AU - Pérez-Hoyos, Santiago
AU - Pillay, Deenan
AU - Ramos, José T.
AU - Tookey, Pat A.
AU - Touloumi, Giota
AU - Warsawski, Josiane
AU - Warszawski, Josiane
AU - Dabis, François
AU - Krause, Murielle Mary
AU - Reiss, Peter
AU - Prins, Maria
PY - 2012
Y1 - 2012
N2 - Despite the increasing success of antiretroviral therapy (ART), virologic failure of the 3 original classes [triple-class virologic failure, (TCVF)] still develops in a small minority of patients who started therapy in the triple combination ART era. Trends in the incidence and prevalence of TCVF over calendar time have not been fully characterised in recent years. Calendar time trends in the incidence and prevalence of TCVF from 2000 to 2009 were assessed in patients who started ART from January 1, 1998, and were followed within the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Of 91,764 patients followed for a median (interquartile range) of 4.1 (2.0-7.1) years, 2722 (3.0%) developed TCVF. The incidence of TCVF increased from 3.9 per 1000 person-years of follow-up [95% confidence interval (CI): 3.7 to 4.1] in 2000 to 8.8 per 1000 person-years of follow-up (95% CI: 8.5 to 9.0) in 2005, but then declined to 5.8 per 1000 person-years of follow-up (95% CI: 5.6 to 6.1) by 2009. The prevalence of TCVF was 0.3% (95% CI: 0.27% to 0.42%) at December 31, 2000, and then increased to 2.4% (95% CI: 2.24% to 2.50%) by the end of 2005. However, since 2005, TCVF prevalence seems to have stabilized and has remained below 3%. The prevalence of TCVF in people who started ART after 1998 has stabilized since around 2005, which most likely results from the decline in incidence of TCVF from this date. The introduction of improved regimens and better overall HIV care is likely to have contributed to these trends. Despite this progress, calendar trends should continue to be monitored in the long term
AB - Despite the increasing success of antiretroviral therapy (ART), virologic failure of the 3 original classes [triple-class virologic failure, (TCVF)] still develops in a small minority of patients who started therapy in the triple combination ART era. Trends in the incidence and prevalence of TCVF over calendar time have not been fully characterised in recent years. Calendar time trends in the incidence and prevalence of TCVF from 2000 to 2009 were assessed in patients who started ART from January 1, 1998, and were followed within the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Of 91,764 patients followed for a median (interquartile range) of 4.1 (2.0-7.1) years, 2722 (3.0%) developed TCVF. The incidence of TCVF increased from 3.9 per 1000 person-years of follow-up [95% confidence interval (CI): 3.7 to 4.1] in 2000 to 8.8 per 1000 person-years of follow-up (95% CI: 8.5 to 9.0) in 2005, but then declined to 5.8 per 1000 person-years of follow-up (95% CI: 5.6 to 6.1) by 2009. The prevalence of TCVF was 0.3% (95% CI: 0.27% to 0.42%) at December 31, 2000, and then increased to 2.4% (95% CI: 2.24% to 2.50%) by the end of 2005. However, since 2005, TCVF prevalence seems to have stabilized and has remained below 3%. The prevalence of TCVF in people who started ART after 1998 has stabilized since around 2005, which most likely results from the decline in incidence of TCVF from this date. The introduction of improved regimens and better overall HIV care is likely to have contributed to these trends. Despite this progress, calendar trends should continue to be monitored in the long term
U2 - https://doi.org/10.1097/QAI.0b013e31823fe66b
DO - https://doi.org/10.1097/QAI.0b013e31823fe66b
M3 - Article
C2 - 22083070
SN - 1525-4135
VL - 59
SP - 294
EP - 299
JO - Journal of acquired immune deficiency syndromes (1999)
JF - Journal of acquired immune deficiency syndromes (1999)
IS - 3
ER -